Creative Planning’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.79M | Buy |
37,608
+10,719
| +40% | +$565K | ﹤0.01% | 1986 |
|
|
2025
Q4 | $1.41M | Sell |
26,889
-2,714
| -9% | -$163K | ﹤0.01% | 2006 |
|
|
2025
Q3 | $1.92M | Buy |
29,603
+13,762
| +87% | +$790K | ﹤0.01% | 1582 |
|
|
2025
Q2 | $770K | Buy |
15,841
+2,263
| +17% | +$87.6K | ﹤0.01% | 2074 |
|
|
2025
Q1 | $462K | Buy |
13,578
+461
| +4% | +$19.5K | ﹤0.01% | 2355 |
|
|
2024
Q4 | $516K | Sell |
13,117
-554
| -4% | -$26.2K | ﹤0.01% | 2191 |
|
|
2024
Q3 | $642K | Sell |
13,671
-1,079
| -7% | -$54.7K | ﹤0.01% | 1890 |
|
|
2024
Q2 | $797K | Buy |
14,750
+456
| +3% | +$26.4K | ﹤0.01% | 1587 |
|
|
2024
Q1 | $974K | Buy |
14,294
+484
| +4% | +$34.6K | ﹤0.01% | 1354 |
|
|
2023
Q4 | $865K | Sell |
13,810
-1,140
| -8% | -$63K | ﹤0.01% | 1316 |
|
|
2023
Q3 | $679K | Buy |
14,950
+5,702
| +62% | +$294K | ﹤0.01% | 1361 |
|
|
2023
Q2 | $519K | Sell |
9,248
-147
| -2% | -$8.34K | ﹤0.01% | 1527 |
|
|
2023
Q1 | $425K | Sell |
9,395
-2,400
| -20% | -$117K | ﹤0.01% | 1573 |
|
|
2022
Q4 | $479K | Sell |
11,795
-182
| -2% | -$9.65K | ﹤0.01% | 1453 |
|
|
2022
Q3 | $783K | Buy |
11,977
+792
| +7% | +$57.4K | ﹤0.01% | 1070 |
|
|
2022
Q2 | $680K | Buy |
11,185
+904
| +9% | +$53.1K | ﹤0.01% | 1145 |
|
|
2022
Q1 | $645K | Buy |
10,281
+491
| +5% | +$30.8K | ﹤0.01% | 1202 |
|
|
2021
Q4 | $742K | Sell |
9,790
-2,380
| -20% | -$208K | ﹤0.01% | 1094 |
|
|
2021
Q3 | $1.36M | Buy |
12,170
+2,742
| +29% | +$344K | ﹤0.01% | 815 |
|
|
2021
Q2 | $1.53M | Sell |
9,428
-3,924
| -29% | -$477K | ﹤0.01% | 774 |
|
|
2021
Q1 | $1.63M | Buy |
13,352
+1,502
| +13% | +$227K | ﹤0.01% | 812 |
|
|
2020
Q4 | $1.81M | Buy |
11,850
+1,391
| +13% | +$164K | ﹤0.01% | 714 |
|
|
2020
Q3 | $875K | Buy |
10,459
+6,240
| +148% | +$554K | ﹤0.01% | 860 |
|
|
2020
Q2 | $310K | Sell |
4,219
-8,317
| -66% | -$486K | ﹤0.01% | 1278 |
|
|
2020
Q1 | $532K | Sell |
12,536
-3,068
| -20% | -$158K | ﹤0.01% | 911 |
|
|
2019
Q4 | $950K | Buy |
15,604
+1,228
| +9% | +$67K | ﹤0.01% | 808 |
|
|
2019
Q3 | $589K | Sell |
14,376
-559
| -4% | -$26.7K | ﹤0.01% | 974 |
|
|
2019
Q2 | $703K | Sell |
14,935
-551
| -4% | -$22K | ﹤0.01% | 906 |
|
|
2019
Q1 | $553K | Buy |
15,486
+695
| +5% | +$24K | ﹤0.01% | 977 |
|
|
2018
Q4 | $423K | Buy |
14,791
+827
| +6% | +$28.8K | ﹤0.01% | 1044 |
|
|
2018
Q3 | $619K | Buy |
+13,964
| New | +$731K | ﹤0.01% | 970 |
|
|
2018
Q1 | – | Sell |
-10,370
| Closed | -$243K | – | 2055 |
|
|
2017
Q4 | $243K | Buy |
+10,370
| New | +$197K | ﹤0.01% | 1480 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Creative Planning's CRSP Position: Q1 2026 in Review
Creative Planning increased its CRISPR Therapeutics (CRSP) stake by 40% in Q1 2026, buying an estimated $565K and bringing the position to 37,608 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1986.
Creative Planning first reported a position in CRSP in Q4 2017 and has held it in 32 quarters since. The position peaked at $1.92M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Creative Planning held 37,608 shares of CRISPR Therapeutics worth $1.79M as of Q1 2026.
- Creative Planning bought 10,719 CRISPR Therapeutics shares in Q1 2026, an estimated $565K.
- CRISPR Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1986 holding.
- Creative Planning first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 32 quarters since.
- Creative Planning's CRISPR Therapeutics position peaked at $1.92M in Q3 2025.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.